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Abstract 
 
The expression and role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18)  in B cells 
are not yet explored in contrast to myeloid cells, where these β2-integrin type receptors are 
known to participate in various cellular functions, including phagocytosis, adherence and 
migration. Here we aimed to reveal the expression and role of CR3 and CR4 in human B 
cells. In B cells of healthy donors CR3 and CR4 are scarcely expressed. However, two 
patients with chronic lymphocytic leukemia (CLL) characterized by a peculiar immune-
phenotype containing both CD5-positive and CD5-negative B cell populations made possible 
to study these molecules in distinct B cell subsets. We found that CD11b and CD11c were 
expressed on both CD5-positive and CD5-negative B cells, albeit to different extents. Our 
data suggest that these receptors are involved in spreading, since this activity of CpG-
activated B cells on fibrinogen could be partially blocked by monoclonal antibodies specific 
for CD11b or CD11c. CpG-stimulation lead to proliferation of both CD5-positive and CD5-
negative B cells of the patients with a less pronounced effect on the CD5-positive cells. In 
contrast to normal B cells, CLL B cells of both patients reacted to CpG-stimulation with 
robust IL-10 production. The concomitant, suboptimal stimulus via the BCR and TLR9 
exerted either a synergistic enhancing effect or resulted in inhibition of proliferation and IL-
10 production of patients’ B cells. 
Our data obtained studying B cells of leukemic patients point to the role of CR3 in the 
interaction of tumor cells with the microenvironment and suggest the involvement of IL-10 
producing B cells in the pathologic process.  
 
 
1. Introduction 
The expression and function of CD11b and CD11c on myeloid cells is known for long. In 
association with CD18, they compose complement receptor type 3 (CR3, comprising 
CD11b/CD18) and type 4 (CR4, comprising CD11c/CD18), which belong to the family of β2 
integrins. These receptors mediate several important cellular functions, including adhesion, 
trans-endothelial migration and interaction with extracellular matrix proteins [1]. By 
interaction with iC3b, the complement-derived natural ligand, CR3 and CR4 mediate the 
uptake of opsonized cells and particles by monocytes, macrophages, neutrophils and dendritic 
cells [2]. Although CR3 and CR4 were thought to exert similar functions, recently we showed 
that they have different roles in various human myeloid cells. Namely, while CR3 dominates 
phagocytosis in the case of dendritic cells [3], CR4 is more important in mediating adherence 
by human monocytes macrophages and dendritic cells [2]. 
Regarding human B cells, the expression and function of CD11b and CD11c by 
various subsets is just being discovered. Appearance of CD11c but not CD11b on activated 
human tonsillar B cells was described in 1991 by Postigo et al. [4]. These authors proved that 
CD11c mediates binding to fibrinogen and may be involved in B cell proliferation. Later, 
Kawai et al showed that CD11b expressed by human memory B cells mediate migration [5].  
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Expression of CD11b, CD11c and CD18 has been reported in various B cell 
malignancies, including B cell chronic lymphocytic leukemia (B-CLL), or chronic 
lymphocytic leukemia (CLL) [6]. B-CLL represents the most common adult B cell tumor, 
which is characterized by the monoclonal expansion of CD5-, CD19- and CD23-positive B 
cells, usually with weak surface Ig expression [7]. CD5 is a pan-T-cell marker, which is 
constitutively expressed also on the long-lived subset of B-1 cells. CD5 is coexpressed with 
CD11b on a smaller population of B-1 cells, which have been shown to spontaneously 
produce IL-10 [8]. CLL demonstrates considerable heterogeneity at clinical, phenotypic as 
well as genomic level, including lack of CD5 expression in 7-20% of the cases [9]. Since the 
survival of the CLL cells is strongly dependent on the stimuli from the microenvironment, 
CD11b, CD11c and CD18 may play a role in proliferation and trafficking of CLL cells. The 
expression of CD11b by B cells of CLL patients was demonstrated by [10]. Later, the 
appearance of CD11c was detected on neoplastic B cells in the case of 52 out of 106 patients 
studied by [11]. Importantly, CD18 was found to be associated with advanced disease in CLL 
(Domingo, Leukemia Research 1997). 
In the present study, we aimed to further characterize and identify the role of CR3 
(CD11b/CD18) and CR4 (CD11c/CD18) in CLL B cells. Selecting two patients with CLL 
characterized by a peculiar immune-phenotype containing both CD5-positive and CD5-
negative B cell populations, provided us with the opportunity to study these molecules in 
distinct B cell subsets. The expression of CR3 and CR4, the proliferative capacity of the cells 
upon BCR and TLR9 triggering and their IL-10 production was thus assessed and compared 
on separated CD5-positive and CD5-negative subpopulations of the patients’ B cells. 
Furthermore, the role of CR3 and CR4 in the capacity of B-CLL cells to adhere and spread 
over fibrinogen coated surface was also investigated. 
 
2. Materials and methods 
2.1. Healthy donors 
Blood samples of healthy donors were purchased from the Hungarian Blood 
Transfusion Service with written informed consent of the donors. Venous blood treated with 
EDTA of two CLL patients was used in the experiments after giving informed consent. The 
study was conducted in accordance with the Declaration of Helsinki and has been approved 
by the Hungarian Medical Research Council Scientific and Research Committee (ETT 
TUKEB, permission number: 21655-1/2016/EKU). 
2.2. Patients 
Patient 1 was diagnosed with chronic lymphocytic leukemia (CLL, Rai stage 0) in 
2010 at age of 71 presenting with 65% lymphocytosis with 40% CD19+ CD5+ CD23+ λ 
monoclonal B cells. These B cells showed low CD38 and intermediate CD20 and CD22 
expression. In 2012, FISH analysis with probes specific for 17p deletion, 11q deletion, 13q 
deletion, 6q deletion and chromosome 12 trisomy was negative. In 2015, lymphocytosis 
increased to 75% with 46% malignant B cells and in addition to the classical CD5+ CLL B 
cells with low surface light chain expression, a CD5- B cell population with normal surface 
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light chain expression could be detected. These CD5- B cells did not show clonal restriction, 
but were considered malignant due to their high CD23 expression. The patient required no 
therapy, she is currently monitored using a watch and wait strategy. 
Patient 2 is a 78-year-old female. CLL was diagnosed in 2009, classified as Rai stage 
0. Characteristics at the diagnosis: 74% lymphocytosis with 35% CD19+ CD5+ CD23+ κ 
monoclonal B cells. These B cells showed low CD38 and intermediate CD20 and CD22 
expression. In 2012, lymphocytosis increased to 81% with 56% CD19+ B cells. By flow 
cytometry analysis, B cells could be divided in two subpopulations. 27% of the B cells 
showed high CD23, intermediate CD19, CD20, CD22, CD5 and no CD81 expression, 
whereas 73% of the B cells showed high CD19, CD20, CD22, intermediate CD23 and partial 
CD5 expression. CD38 expression was still low on all B cells. FISH analysis with probe 
specific for p53 deletion was negative. In 2015, lymphocytosis increased, 88% lymphocytes 
in whole blood with 73% malignant B cells. Two B cell populations were identified, 40% of 
the B cells showed high CD19, CD20, intermediate CD200, CD23, κ light chain and no CD5 
and CD38, whereas the other 60% showed intermediate CD19, CD20, CD200, high CD5, 
CD23 and no surface light chain expression. Similar to Patient 1, this patient required no 
therapy either, she is currently monitored using a watch and wait strategy. 
Samples were available from both patients on five occasions within a period of 15 
months. 
 
2.3. Cell isolation, flow cytometry and cell sorting 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque 
(Sigma-Aldrich Inc., St Louis, MO) density gradient centrifugation from buffy coat or 
patients’ EDTA-treated venous blood. Patients’ B cells were purified by negative selection 
using the Miltenyi B-CLL Cell Isolation Kit achieving > 99% purity. B cells of healthy 
controls were purified by negative selection using the Miltenyi B Cell Isolation Kit II 
achieving ~80-95% purity. 
For flow cytometry analyses, cells were labelled with mouse monoclonal antibodies 
against CD11b (clone TMG6-5, provided by István Andó at BRC Szeged, Hungary and clone 
ICRF44, BioLegend), CD11c (clone BU15, ImmunoTools GmbH, Friesoythe, Germany), 
CD21 (clone LT21, ImmunoTools) and CD35 (clone UJ11, ImmunoTools) and after washing 
cells were stained with Alexa488-conjugated donkey anti-mouse antibodies (Thermo Fisher 
Scientific Inc., Waltham, MA). After blocking with mouse serum, patients’ B cells were 
stained with APC-conjugated anti-CD5 (clone LT1, ImmunoTools), and B cells of healthy 
controls with APC-conjugated anti-CD19 (clone LT19, ImmunoTools. B cell receptor 
expression was analysed by labelling the cells with goat anti-IgD F(ab’)2 (Southern Biotech) 
or goat anti-IgM F(ab’)2 (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) and 
Alexa488-conjugated rabbit anti-goat antibodies (Thermo Fisher Scientific) or FITC-
conjugated goat anti-IgG F(ab’)2 (Jackson ImmunoResearch Laboratories). Measurement was 
performed on a FACS Calibur cytometer (BD Biosciences, San Jose, CA) using the CellQuest 
software and data were analysed using the FlowJo software (Treestar, Ashland, OR, USA). 
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For analysis of CD5-positive and CD5-negative B cell populations, cells were stained with 
FITC-conjugated anti-CD19 (clone LT19, ImmunoTools) and APC-conjugated anti-CD5 and 
sorted using a FACS Aria III instrument and the FACSDiva software. 
 
2.4. Quantitative real-time PCR analysis 
 Total RNA was extracted from sorted CD19-positive CD5-negative and CD19-
positive CD5-positive cells of the patients obtained at three independent time-points as well as 
sorted CD19-positive B cells of healthy controls using Trizol reagent (Ambion) as 
recommended by the manufacturer. One microgram of RNA was reverse transcribed with the 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies) according to the 
manufacturer’s instructions. mRNA levels were quantified using the following TaqMan® 
assays: CD11b: Hs01064805_m1, CD11c: Hs00174217_m1, CD21: Hs01079100_m1, CD35: 
Hs00355835_m1. Samples were run in duplicates on a QuantStudio™ 3 Real-Time PCR 
System (Life Technologies) and results were obtained as threshold cycle (Ct) values. 
Expression values were calculated as the mean of duplicates and normalized to the expression 
of β-glucuronidase (Hs99999908_m1) using the Ct method. 
 
2.5. Cell culture and proliferation assay 
Purified B cells of healthy donors and sorted CD5-negative and CD5-positive B cells 
of the patients were seeded onto 96-well flat bottom culture plates (Greiner Bio-One, 
Kremsmünster, Austria) at 2 × 105 cells/well density in 200 µl RPMI-1640 medium 
containing 10% FCS and gentamycin. CpG-activated cells were cultured in the presence of 50 
ng/ml recombinant human IL-2 (ImmunoTools) and 0.5 µg/ml CpG-ODN 2006 (Sigma) for 5 
days. In proliferation assays, purified B cells of healthy donors and sorted CD5-positive and 
CD5-negative B cells of the patients were plated at 2 × 105 cells/well density in 100 µl 
medium containing 50 ng/ml IL-2. Cell culture wells were precoated with 2.5 µg/ml goat anti-
human IgG+A+M F(ab’)2 (Jackson ImmunoResearch Inc.) plus 2.5 µg/ml goat anti-human 
IgD F(ab’)2 (Southern Biotech) and cells were stimulated with 0.5 µg/ml CpG ODN 2006 
where indicated. Proliferation was assessed by measuring 3H-thymidine incorporation. After 
48 hours cells were pulsed with 1 μCi/well 3H-thymidine (NEN, Boston, MA) for 18 hours. 
Incorporated radioactivity was measured with a Wallac 1409 liquid scintillation beta counter 
(Wallac, Allerod, Denmark). Data are expressed as cpm (count per minutes) values and are 
mean of triplicates + SD. 
 
2.6. Measurement of adherence 
96-well cell culture plates were coated with 10 µg/ml fibrinogen (Merck, Budapest, 
Hungary) for 1 h at 37°C and washed with phosphate buffered saline (PBS). 105 freshly 
isolated or activated (50 ng/ml IL-2 and 0.5 µg/ml CpG-ODN for 5 days) B cells were seeded 
onto the wells and let adhere for 1 h at 37°C. After fixing with 2% paraformaldehyde, 
unbound cells were washed away. The cells were stained with mouse anti-CD19 
(Pharmingen, BD) and Alexa647-conjugated goat anti-mouse Ig (Thermo Fisher Scientific) 
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and the actin cytoskeleton was stained with Alexa488-conjugated phalloidin (Molecular 
Probes). In blocking experiments, activated B cells were incubated with FcR blocking reagent 
(Miltenyi Biotech) for 10 minutes at 4°C then labelled with APC-conjugated anti-CD5 for 20 
min at 4°C. After washing, cells were incubated in medium alone, with 10 µg/ml anti-CD11b 
(clone ICRF44) or with anti-CD11c (clone BU15) for 30 min at 4°C. To ensure that recycled 
integrins from the cytoplasm are also blocked, the antibodies were not washed out. Cells were 
then allowed to adhere to fibrinogen-coated wells for 1 h at 37°C. After fixing and washing, 
nuclei were stained with Draq5 (Molecular Probes) and the actin cytoskeleton with Alexa488-
conjugated phalloidin. Images were taken by an Olympus IX81 laser scanning confocal 
microscope using the FluoView500 software. Ten representative fields were scanned in each 
well and nuclei were counted using ImageJ software. 
The area, perimeter and circularity parameters were measured for 100 cells/treatment 
based on the actin staining using ImageJ software. Circularity is calculated by the following 
formula (the value is between 0-1, with a perfect circle’s value being 1): 4π × [Area] / 
[Perimeter]2. Cells with a circularity value < 0.35 were counted as “spread out”. 
 
2.7. Measurement of IL-10 production 
Purified B cells of healthy donors and sorted CD5-positive and CD5-negative B cells 
of the patients were plated onto 96-well cell culture plates at 2 × 105 cells/well density in 
duplicates and stimulated as described for the proliferation assay. After 48 hours, IL-10 
content of the supernatant was measured using IL-10 Duoset ELISA system (R&D Systems, 
Minneapolis, USA) according to the manufacturer’s instructions. 
 
2.8. Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, California). A p value < 0.05 was considered statistically 
significant. 
 
3. Results 
 
3.1. Complement receptor expression of CLL B cells 
 Although sporadic data are available regarding the expression of complement 
receptors binding various activation fragments of component C3, namely CR1 (CD35), CR2 
(CD21), CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in CLL [6, 12, 13], so far the B cell 
populations of the same patient were not screened in parallel. To get a complex picture, in our 
studies complement receptor expression was assessed employing the isolated B cells of each 
patient. We determined CR expression on the CD5-negative as well as the CD5-positive B 
cell populations. 
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We measured CD11b and CD11c expression on the patients’ B cells by flow 
cytometry. In the case of Patient 1, CD11b was present on the majority of B cells, and only a 
small subset of CD5-positive cells showed low expression of the receptor (Figure 1). By 
contrast, CD11c was generally weakly expressed, whereas the CD5-positive subset showed 
strong expression. CD5-positive B cells of Patient 2 had very weak CD11b but strong CD11c 
expression, whereas CD5-negative B cells expressed CD11b but not CD11c. Gating on 
CD19-positive B cells of healthy donors, neither CD11b nor CD11c could be detected. 
To get a complex picture of complement receptors, expression of CD35 and CD21 was 
also measured. CD35 was expressed on both the CD5-negative and CD5-positive B cells of 
Patient 1, while in the case of Patient 2 only CD5-negative B cells expressed CD35. CD21 
was present on all B cells of both patients. CD19-positive B cells of a healthy donor expressed 
both CD21 and CD35. 
Expression of CD11b, CD11c, CD21 and CD35 at mRNA level was also determined 
and compared to that of normal B cells of healthy donors. Patients’ B cells were sorted and 
CR expression of the CD19-positive CD5-negative and CD19-positive CD5-positive 
populations were analysed. B cells of healthy donors were sorted based on CD19-positivity. 
Results were normalized to the expression of the housekeeping gene β-glucuronidase. All CR 
mRNAs were detectable in both the CD5-negative and CD5-positive B cell populations of the 
patients as well as in B cells of healthy donors, even when surface expression of the CR 
proteins were not detectable by flow cytometry (Figure 2). 
 
3.2. Proliferation of CLL B cells  
Next, the proliferative capacity of the CD5-positive and CD5-negative subpopulations 
of B-CLL patients and B cells of healthy individuals was compared. CLL B cells with 
mutated Ig genes are known to become anergic in response to stimulation via BCR [14] while 
unmutated CLL retains sIg mediated signalling [15]. Recently, Chatzouli et al. showed that 
concomitant engagement of BCR and TLR9 exerts a heterogeneous effect depending on the 
mutational status of sIg [16].  
Our results show that CpG induces strong proliferation of CD5-negative B cells of 
both patients, as well as B cells of healthy controls. CD5-positive CLL B cells also proliferate 
in response to CpG, however, to a lesser extent (Figure 3). The suboptimal dose of anti-BCR 
stimulus used in these experiments resulted in a weak activation of Patient 1’s B cells and B 
cells of healthy individuals, and had no effect in the case of Patient 2. Simultaneous, 
suboptimal stimulus by CpG and anti-BCR synergistically enhanced proliferation of Patient 
1’s CD5-negative B cells, similar to B cells of healthy controls, but not of CD5-positive B 
cells. Interestingly, both CD5-positive and CD5-negative B cells of Patient 2 showed weaker 
proliferation in response to the combined stimulus than to CpG alone. This might have been 
caused by differences in BCR expression of the CD5-negative and the CD5-positive 
populations of the patients’ B cells, as detailed in the section of Materials and Methods. 
 
3.3. CpG stimulation leads to IL-10 production  
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CLL B cells are known to secrete high amounts of the anti-inflammatory cytokine IL-
10, mainly due to their elevated CD5 expression [17]. To test whether there is a difference 
between the CD5-negative and CD5-positive B cells of the patients regarding this ability, IL-
10 production was measured from cell culture supernatants after stimulation with anti-BCR, 
CpG and their combination. 
We found that unstimulated B cells of both patients and those of healthy controls 
produced negligible amount of IL-10, similarly to their response to a suboptimal BCR-
stimulus (Figure 4). By contrast, CpG caused a robust IL-10 production by the patients’ B 
lymphocytes with a more pronounced effect on the CD5-positive B cells, but only slightly 
increased IL-10 secretion of normal B cells. The effect of the combined stimulus did not 
differ from that of CpG alone in case of CD5-positive cells of the patients as well as of 
normal B cells of healthy controls. However, CD5-negative B cells of Patient 1 produced 
higher amount of IL-10 when CpG stimulus was combined with anti-BCR stimulus, while it 
had an inhibitory effect on CD5-negative B cells of Patient 2. 
 
3.4. CpG stimulation leads to changes in CR3 and CR4 expression 
Next we set out to investigate whether stimulation of the cells induces any changes in 
the expression of the β2-integrin family members, CR3 and CR4. As seen in Figure 5, CpG-
stimulation lead to changes in CR-expression by the patients’ B cells. In the case of Patient 1, 
the CD5-positive and the CD5-negative B cells had similar characteristics. Flow cytometry 
analysis revealed decreased CD11b expression compared to the freshly isolated cells, while 
no staining with CD11c was seen. CpG-stimulated Bcells of Patient 2 showed a similar 
pattern to that of freshly isolated cells, however, expression of CD11b and CD11c was less 
intensive. CD5-negative cells were still negative for CD11b. 
 
3.5. Blocking CR3 or CR4 on CpG-activated CLL B cells decreases spreading on fibrinogen 
CLL B cells of both patients adhered to fibrinogen (Figure 6), whereas adhesion of 
normal B cells could not be seen under the conditions used (data not shown). Freshly isolated 
CLL B cells were small and round, showing typical B cell morphology. Although the cells 
expressed CR3 and/or CR4 (Figure 1), blocking CD11b or CD11c had no influence on the 
adhesion of the cells (data not shown). By contrast, CpG-activated cells were significantly 
larger and prone to spread, shown by actin cytoskeleton staining (Figure 6). CR3- and CR4-
expression in response to CpG decreased (Figure 5), though their role in adhesion of the 
activated cells to fibrinogen could be demonstrated. Preincubation of the cells with 
monoclonal antibodies specific to the ligand binding site of CD11b and CD11c partially 
inhibited spreading of the cells (Figure 7). 
 
4. Discussion 
 While the expression and function of CD11b and CD11c on myeloid cells is known 
for long, the possible role of CR3 and CR4, the β2-integrin type complement receptors in 
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various functions of B cells is just being discovered. In order to get a deeper insight into the 
proliferative capacity, IL-10 production and adherence of CR3 and CR4 expressing B 
lymphocytes, we selected for our studies two CLL patients with a peculiar immune-phenotype 
containing both CD5-positive and CD5-negative B cell populations. Our results are 
summarized in Table 1. 
 In contrast to healthy individuals, where we could detect neither CD11b nor CD11c 
on the CD19-positive population, B cells of both CLL patients expressed CR3 and CR4, 
although with different intensity (Figure 1 and Table 1). CD5-positive and CD5-negative B 
cell populations of Patient 1 had similar characteristics with strong CD11b and weak CD11c 
expression, except for a small CD5-positive population that was positive only for CD11c. B 
cells of Patient 2, however, were different: CD5-positive cells expressed CD11c, while CD5-
negative cells CD11b. This difference between the patients is probably explicable by the 
different origin of the CD5-negative populations. CD5-negative B cells of Patient 1 do not 
show clonal restriction, whereas CD5-negative B cells of Patient 2 are thought to originate 
from the CD5-positive clone (see Patient description). Although in our present study we did 
not aim to investigate the expression and function of complement receptor type 1 (CD35) and 
2 (CD21), to get a more complex view, these receptors were also included in the screening 
both at the mRNA and protein levels. CD5-positive CLL B cells are reported to partially or 
completely lose CD35 and decrease CD21 expression. In accordance with this, we found that 
CD21 was expressed on the cell surface of both the CD5-positive and CD5-negative 
subpopulations of the patients and in the case of Patient 2 CD35 was lost on the CD5-positive 
cells. CD5-positive B cells of Patient 1, however, strongly expressed CD35. 
In the proliferation assay, CD5-negative B cells of both patients showed robust 
proliferation in response to CpG-treatment, similar to normal B cells (Figure 3 and [18]). 
Furthermore, in agreement with the observation of Decker et al. [19], CD5-positive CLL B 
lymphocytes of both patients’ showed remarkable proliferation to CpG stimulation, which 
might correlate with these cells’ higher expression of TLR9, the main receptor for CpG [20]. 
In contrast to the strong response to CpG, triggering via the BCR did not induce a notable 
proliferation of B cells under the experimental conditions used. The low response to the BCR-
mediated stimulus partially might be due to the anergic state of B cells, which is a 
characteristic feature in mutated CLL. In addition, we used suboptimal dose of BCR-stimulus 
to analyze the synergistic effect of the anti-BCR and CpG stimuli. The combined trigger 
enhanced the proliferation of Patient 1’s CD5-negative B cells – similarly to the results 
obtained with cells of healthy donors –, and induced a weaker response in the case of Patient 
2’s B lymphocytes when compared to the trigger by CpG alone. Our data point to the 
modulation of BCR-mediated trigger by additional stimuli to induce proliferation of CLL B 
cells, a phenomenon which might be particularly important under pathological conditions. 
Our finding that CD5-positive B cells are less reactive than the CD5-negative ones 
might partially be due to the low expression of surface immunoglobulins and the negative 
regulatory effect of CD5 molecule. This latter had already been proven in the case of the BCR 
signaling pathway [21-23]. Furthermore, Jahrsdörfer et al. found that in response to CpG, the 
CD5-negative population of CLL B cells undergo more divisions than the CD5-positive cells 
[24]. In line with these data, we found that CpG treatment alone promoted mainly the 
proliferation of the CD5-negative B cells, particularly in the case of Patient 2. 
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In healthy individuals, IL-10 secreting B cells – termed B10 cells – normally represent 
only a very small proportion of blood B cells [25, 26]. In contrast to this, B cells of CLL 
patients possess the capacity to secrete substantial amounts of IL-10 that can promote 
leukemic cell survival via immunosuppression [25, 27]. In agreement with these data, we 
found a much higher – up to ten-fold – amount of IL-10 in the supernatant of stimulated B-
CLL cells than in the case of healthy controls. Our data demonstrate that in addition to – or 
parallel with – the strong proliferative effect of CpG, this agonist also induces a significant 
IL-10 production by both the CD5-positive and CD5-negative subpopulations of the patients’ 
B cells, supporting the data of Chen et al. [20]. In response to the combined anti-BCR and 
CpG trigger, the CD5-positive B cells of the patients did not produce much higher amount of 
IL-10 than to CpG treatment alone – which might be again due to the suboptimal BCR-
trigger, decreased surface immunoglobulin expression and anergic state of the malignant cells. 
Data on IL-10 secretion of CD5-negative CLL B cells are not available in the literature. The 
pattern of IL-10 production of the CD5-negative B cells in response to the combined anti-
BCR and anti-TLR9 stimulus is remarkably similar to that of proliferation. This might suggest 
that the higher amount of secreted IL-10 is not the result of differentiation but is rather due to 
the increased number of cells in the culture. In agreement with the known IL-10 synthesis 
promoting effect of CD5, we detected elevated IL-10 secretion of CD5-positive cells in the 
case of Patient 2 in response to CpG-treatment alone or its combination with BCR ligation 
[17]. 
Activation of patients’ B cells via TLR9 leads to changes in expression of CR3 and 
CR4, as well as changes in morphology of fibrinogen-adhered cells. Stimulation with CpG 
induced spreading of the cells measured by the area of adhered cells (Figure 6). Expression of 
the analyzed integrins CR3 and CR4 was reduced on CpG-treated cells (Figure 5) still, there 
was no difference in the number of adhered cells on fibrinogen coat between freshly isolated 
and CpG-stimulated cells. This suggests that adhesion of CLL B cells to fibrinogen is 
mediated mainly via other integrins. Since spreading of CpG-activated B cells of the patients 
on fibrinogen, which could be incompletely blocked by monoclonal antibodies specific for 
CR3 or CR4, we suppose that these receptors are partially responsible for mediating spreading 
in response to activating stimuli (Figure 7). CR3 was also implicated in the protection against 
fludarabine-induced apoptosis of CLL B cells when binding another of its natural ligands, the 
complement fragment iC3b [28]. Similar roles, namely mediating adhesion/spreading and 
protection against apoptosis against anti-cancer drugs are attributed to another integrin, 
CD49d (VLA-4) [29].  
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Table 1. Characteristics of CLL B cells from Patients 1 and 2. 
Patient CD5 expression 
CR3 
(CD11b/ CD18) 
expression 
CR4 
(CD11c/ CD18) 
expression 
Proliferation 
in response to 
CpG 
Proliferation 
in response to 
CpG +BCR 1 
IL-10 secretion 
in response to 
CpG 
IL-10 secretion 
in response to 
CpG +BCR 2 
Spreading of CpG-
stimulated cells on 
fibrinogen 3 
1. 
CD5- 
negative +++ + ++ +++ ++ +++ 
++ 
partial inhibition by 
anti-CD11b 
 
CD5-
positive +++/- 
4 +/+++ 4 + + ++ ++ 
2. 
CD5- 
negative ++ - +++ ++ ++ + 
++ 
partial inhibition by 
anti-CD11b and 
anti-CD11c 
CD5- 
positive (+) ++ ++ (+) +++ ++ 
1 Cells were stimulated with suboptimal anti-BCR stimulus, which alone did not induce notable proliferation 
2 Cells were stimulated with suboptimal anti-BCR stimulus, which alone did not induce notable IL-10 production 
3 Unseparated CD5-negative and CD5-positive cells were investigated 
4 Signs after ‘/’ denote a small CD5-positive subset showing characteristics distinct from the majority of CD5-positive cells 
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